224 related articles for article (PubMed ID: 30773756)
1. Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective.
Sumnik Z; Szypowska A; Iotova V; Bratina N; Cherubini V; Forsander G; Jali S; Raposo JF; Stipančic G; Vazeou A; Veeze H; Lange K;
Pediatr Diabetes; 2019 Jun; 20(4):434-443. PubMed ID: 30773756
[TBL] [Abstract][Full Text] [Related]
2. Variations in access to and reimbursement for continuous glucose monitoring systems for people living with Type 1 diabetes across England.
Perera R; Oliver N; Wilmot E; Marriott C
Diabet Med; 2018 Nov; 35(11):1617-1618. PubMed ID: 29931731
[No Abstract] [Full Text] [Related]
3. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
Rubin RR; Peyrot M
J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
[TBL] [Abstract][Full Text] [Related]
5. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study.
Charleer S; De Block C; Van Huffel L; Broos B; Fieuws S; Nobels F; Mathieu C; Gillard P
Diabetes Care; 2020 Feb; 43(2):389-397. PubMed ID: 31843948
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
[No Abstract] [Full Text] [Related]
7. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy.
; Weinzimer S; Xing D; Tansey M; Fiallo-Scharer R; Mauras N; Wysocki T; Beck R; Tamborlane W; Ruedy K
Pediatr Diabetes; 2009 Apr; 10(2):91-6. PubMed ID: 19175899
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
St Charles M; Lynch P; Graham C; Minshall ME
Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
[TBL] [Abstract][Full Text] [Related]
9. Optimization of insulin regimen and glucose outcomes with short-term real-time continuous glucose monitoring (RT-CGM) in type 1 diabetic children with sub-optimal glucose control on multiple daily injections: The pediatric DIACCOR study.
Picard S; Bonnemaison-Gilbert E; Leutenegger E; Barat P
Arch Pediatr; 2019 Feb; 26(2):95-101. PubMed ID: 30642746
[TBL] [Abstract][Full Text] [Related]
10. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
11. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
12. Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry.
Szypowska A; Schwandt A; Svensson J; Shalitin S; Cardona-Hernandez R; Forsander G; Sundberg F; De Beaufort C; Maahs D; Maffeis C; O'Riordan SM; Krisane ID; Scharf M; Castro S; Konstantinova M; Obermannova B; Casteels K; Gökşen D; Galhardo J; Kanaka-Gantenbein C; Rami-Merhar B; Madacsy L;
Pediatr Diabetes; 2016 Oct; 17 Suppl 23():38-45. PubMed ID: 27417128
[TBL] [Abstract][Full Text] [Related]
13. Skin Problems Associated with Insulin Pumps and Sensors in Adults with Type 1 Diabetes: A Cross-Sectional Study.
Berg AK; Nørgaard K; Thyssen JP; Zachariae C; Hommel E; Rytter K; Svensson J
Diabetes Technol Ther; 2018 Jul; 20(7):475-482. PubMed ID: 29893593
[TBL] [Abstract][Full Text] [Related]
14. Comparison of flash glucose monitoring with real time continuous glucose monitoring in children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion.
Massa GG; Gys I; Bevilacqua E; Wijnands A; Zeevaert R
Diabetes Res Clin Pract; 2019 Jun; 152():111-118. PubMed ID: 31121275
[TBL] [Abstract][Full Text] [Related]
15. Changing costs of type 1 diabetes care among US children and adolescents.
Crossen S; Xing G; Hoch JS
Pediatr Diabetes; 2020 Jun; 21(4):644-648. PubMed ID: 32061049
[TBL] [Abstract][Full Text] [Related]
16. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.
Galderisi A; Sherr JL
Pediatr Ann; 2019 Aug; 48(8):e311-e318. PubMed ID: 31426099
[TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
[TBL] [Abstract][Full Text] [Related]
18. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital.
Umpierrez GE; Klonoff DC
Diabetes Care; 2018 Aug; 41(8):1579-1589. PubMed ID: 29936424
[TBL] [Abstract][Full Text] [Related]
19. Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study.
Gajewska KA; Biesma R; Bennett K; Sreenan S
Acta Diabetol; 2021 Jan; 58(1):93-105. PubMed ID: 32862261
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study.
Šoupal J; Petruželková L; Flekač M; Pelcl T; Matoulek M; Daňková M; Škrha J; Svačina Š; Prázný M
Diabetes Technol Ther; 2016 Sep; 18(9):532-8. PubMed ID: 27482825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
